Dermatology

Novartis has won the first FDA approval for symptomatic dermographism. Rhapsido (remibrutinib) is now cleared for adults whose hives and itch stay uncontrolled on H1 antihistamines, with 29.3% of patients achieving complete hive resolution at Week 12 against 14.0% on placebo. #SyenzaNews #dermatology #MarketAccess

Can AI make skin cancer detection fairer across skin tones? 🩺🤖 A lesion-attention AI model that focuses on the lesion area reduces diagnostic bias and improves accuracy for darker skin tones while maintaining overall performance, offering a practical step toward more equitable dermatology tools. The paper details model design, evaluation on diverse datasets, and implications for clinical deployment. Read the full article to explore the methods, results, and what this means for clinicians, developers, and policymakers. #SyenzaNews #medicalimaging #AIinHealthcare #ai #innovation

💡 What if you could improve the treatment of inflammatory diseases with just one breakthrough drug? MoonLake Immunotherapeutics HS is doing just that with Sonelokimab, a game-changing therapy for hidradenitis suppurativa targeting the root causes of inflammation. With a strategic focus on innovative financing and operational efficiency, MoonLake is setting new standards in the biotech industry. Dive into how they’re transforming the future of immunotherapy and addressing critical healthcare gaps! #SyenzaNews #healthcare #biotechnology #MarketAccess

🌟 Are you ready to improcve the way we treat chronic hand eczema? The FDA's recent approval of ANZUPGO® (delgocitinib cream) marks a groundbreaking advancement in treating moderate-to-severe chronic hand eczema (CHE), offering a targeted solution that stands out in the dermatologic landscape. With its unique pan-JAK inhibition mechanism, ANZUPGO promises to improve patient outcomes significantly while minimizing systemic risks. Jump into the article to understand how this approval could reshape standard-of-care practices for CHE and enhance the quality of life for millions. #SyenzaNews #HealthcareInnovation #DrugDevelopment #PrecisionMedicine